The effect of pay for performance on risk incidence of hip fracture in type 2 diabetic patients: a nationwide population-based cohort study

Yung-Heng Lee, MD\textsuperscript{a,b,c,d}, Pei-Tseng Kung, ScD\textsuperscript{e,f}, Wei-Yin Kuo, MHA\textsuperscript{a}, Su-Ling Kao, MHA\textsuperscript{d,g}, Wen-Chen Tsai, DR PH\textsuperscript{a,h,*}

Abstract

Objectives: Diabetes mellitus (DM) increases the risk of hip fracture. The literature rarely discusses the importance of pay-for-performance (P4P) programs for the incidence of hip fractures in patients with type 2 DM (T2DM). This study aimed to examine the impact of the P4P program on hip fracture risk in patients with T2DM.

Methods: This retrospective cohort study focused on data from T2DM patients aged 45 and older between 2001 and 2012. We continued to track these data until 2013. The data were collected from the National Health Insurance Research Database in Taiwan. To minimize selection bias, T2DM patients were divided into P4P enrollees and non-enrollees. Propensity score matching by greedy matching technique (1:1 ratio) was used to include 252,266 participants. A Cox proportional hazard model was performed to examine the impact of the P4P program on hip fracture risk. We used the bootstrap method to perform sensitivity analysis by random sampling with replacement.

Results: Our results showed that the risk of hip fracture in P4P enrollees was 0.92 times that of non-enrollees. (hazard ratio [HR] = 0.92; 95% confidence interval [CI]: 0.85–0.99). P4P enrollees who received regular treatment had lower risk in the first 4 years (HR = 0.90; 95%CI: 0.84–0.96) but no statistically significant difference after 4-year enrollment (HR = 0.99; 95%CI: 0.93–1.06). There was no statistically significant difference in the effect of hip fractures between P4P non-enrollees and P4P enrollees with irregular treatment (HR = 0.94, 95%CI: 0.87–1.03). Through sensitivity analysis, the results also showed P4P enrollees had a lower risk of hip fracture compared to P4P non-enrollees (mean HR = 0.91; 95% CI: 0.91–0.926). Stratified analysis showed that patients without DM complications (DCSI = 0) who enrolled in P4P had lower risks of hip fractures than the non-enrollees (HR = 0.90; 95% CI: 0.82–0.98).

Conclusion: T2DM patients enrolled in P4P program can reduce the risks of hip fracture incidence. Early inclusion of patients without DM complications in the P4P program can effectively reduce hip fractures.

Abbreviations: CCI = Charlson’s Comorbidity Index, CI = confidence interval, DCSI = diabetes complications severity index, DM = diabetes mellitus, HR = hazard ratio, NHIRD = National Health Insurance Research Database, P4P = pay for performance, PSM = propensity score matching, T2DM = type 2 diabetes mellitus.

Keywords: diabetes mellitus, hip fracture, pay for performance, Type II diabetes mellitus.

1. Introduction

According to the 2016 statistics of causes of death by the Ministry of Health and Welfare and Statistics Department, diabetes mellitus (DM) was ranked fifth in 2016.\textsuperscript{[1]} From 2000 to 2009, diabetic patients in Taiwan increased by 70%, reaching 1.2 million, equivalent to an adult incidence of 6.4%.\textsuperscript{[2]} Research shows that 450 out of every 100,000 people in Taiwan sustained hip fractures. Taiwan’s prevalence of hip fracture follows only Denmark, Sweden, Norway, the United States, and Austria, ranked 7th worldwide, and is the highest among Asian nations.\textsuperscript{[3]}

Editor: Danny Chu.

YHL, PTK and WCT, authors have equal contributions to this work.

This study was supported by the grant (ASIA106-CMUH-11) from China Medical University and Asia University.

The authors have no conflicts of interest to disclose.

\textsuperscript{a} Department of Health Services Administration, Taichung, \textsuperscript{b} Department of Public Health, China Medical University, \textsuperscript{c} Department of Orthopedics, Chihsing General Hospital, Kaohsiung, \textsuperscript{d} Department of Center for general education, National United University, Miaoli, \textsuperscript{e} Department of Healthcare Administration, Asia University, \textsuperscript{f} Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, \textsuperscript{g} Department of Human Resource, Chihsing General Hospital, Kaohsiung, Taiwan, ROC.

Correspondence: Wen-Chen Tsai, No.91 Hsueh-Shih Road, Taichung, Taiwan 40402, R.O.C. (e-mail: wtsai@mail.cmu.edu.tw).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Lee YH, Kung PT, Kuo WY, Kao SL, Tsai WC. The effect of pay for performance on risk incidence of hip fracture in type 2 diabetic patients: a nationwide population-based cohort study. Medicine 2020;99:12(e19592).

Received: 23 April 2019 / Received in final form: 22 January 2020 / Accepted: 18 February 2020

http://dx.doi.org/10.1097/MD.0000000000019592
Hip fractures often require hospitalized surgical treatment, and exhibit high rates of complications and mortality; mortality is 8.4% to 36% each year.[6]

Many studies have previously investigated the relationship between medications and hip fractures. Among these, common drugs that increase the risks of fracture include: glucocorticoids,[1,6] anticonvulsants;[7] drugs that reduce the risk of fracture include: calcium,[8] vitamin D,[9] and bisphosphonates;[10] and loop diuretics may either increase or reduce the risk of fracture.[11]

Diabetic patients exhibit relatively higher risk of hip fractures than non-diabetic patients, with a relative risk (RR) of 1.8.[12] Chinese diabetic patients in Singapore have an RR of 1.98 for hip fracture; longer durations of diagnosed DM led to higher risks of hip fracture. Compared to non-DM patients, patients diagnosed with DM for less than 5 years have an RR of 1.8, whereas those diagnosed for longer than 15 years have an RR of 2.66.[13] 1997–2002 National Health Insurance Research Database (NHIRD) research also showed that the incidence of hip fracture in diabetic patients was higher to those of non-diabetic patients in varying genders and ages.[14]

In November 2001, the National Health Insurance Administration of the Ministry of Health and Welfare started the diabetic pay for performance (P4P) program and introduced the concept of shared care and inclusion of administrative procedures within disease care management. The program is a method of insurance payment based on a disease management program. The program objectives are as follows:

(1) Establish a patient-centered, shared care model.
(2) Increase compliance to diabetes treatment guidelines.
(3) Construct a quality-oriented payment system.

Physicians, nurses, case managers, nutritionists, and other medical professional personnel are teamed to provide diabetic patients with regular inspections, exams, health education, and outpatient tracking. Many studies have indicated that implementing P4P increases quality and satisfaction of medical care for diabetic patients, and reduces diabetes complications.[15,16] Diabetic patients who participated in P4P programs receive more continuing care than do non-P4P enrollees.[17] In medical resource consumption, research shows that after diabetic patients join P4P programs, outpatient visits, laboratory measurement items, and test frequency increase. However, annual admission days and total medical cost are lower in P4P groups.[18]

There are presently few studies exploring whether type 2 DM (T2DM) patients’ participation in pay for P4P programs has a significant influence on their incidence of hip fractures. This study investigated whether the P4P enrollment of T2DM patients had an influence on their incidence of hip fracture.

2. Materials and methods

2.1. Study design

This study adopted a retrospective cohort study methodology and focused on data from T2DM patients aged 45 and older between 2001 and 2012. We continue to track these data until 2013. The research data were retrieved from the NHIRD. All data had been fully anonymized before we accessed them and personal privacy was under protection from using these data. The study was passed by the Institutional Review Board of China Medical University (CMU). The approval number is CMUH103-REC-003.

2.2. Patient selection

In this study, diabetic patients are defined as those who have been hospitalized once within 365 days or who have at least 3 primary or secondary outpatient diagnoses of DM (International Classification of Diseases, Ninth Revision, Clinical Modification of 250.XX). This study focused solely on T2DM patients and thus did not include patients with type 1 diabetes, neonatal diabetes, gestational diabetes, or impaired oral glucose tolerance. T2DM patients who were diagnosed with T2DM for more than 1 year before participating in the P4P program, died within 3 months after diagnosis with T2DM, had hip fractures before they were diagnosed with T2DM, had hip fractures within 3 months after they had been diagnosed with T2DM, had missing data, and were under 45 years of age were excluded. The hip fracture patients in this study are defined as patients who sustained femoral neck fracture, intertrochanteric fracture, or subtrochanteric fracture and required hospitalization and surgical treatment; and whose primary or secondary International Classification of Diseases, Ninth Revision, Clinical Modification diagnoses are 820.XX. The surgical codes were hemiarthroplasty (International Classification of Diseases [ICD] 81.52), open reduction and internal fixation (ICD 79.35), and close reduction and internal fixation (ICD 79.15).

The P4P enrollees and non-enrollees exhibited numerous inherent differences in basic characteristics. To minimize selection bias, they were divided into P4P enrollees and non-enrollees. The propensity score matching (PSM) was applied by using 1:1 matching ratio. The way to form a subject matching set was through greedy matching by digit without replacement.[19]

2.3. Study variables

In this study, the independent variable was whether or not the T2DM patients enrolled in a P4P program. The P4P enrollees were divided according to Yu et al (2014) into regular treatment patients, who received medical treatment at least once every 3 months and 4 times each year, and irregular treatment patients.[20] The controlled variables were demographics (age, gender, monthly salary, and urbanization of residence area); health status (comorbidity, severity of diabetes complications, and presence or absence of catastrophic illness); characteristics of healthcare organization (physician’s annual service volume, level of healthcare organization, and ownership of organization); and medication status (steroids, anticonvulsants, diuretics, calcium, vitamin D, or bisphosphonates). The dependent variable was the hip fracture incidence of the diabetic patients and follow-up time. Monthly salaries were used to measure the patient’s socioeconomic status. The income levels are divided into 7 levels: low-income households; < NT$17,800, NT$17,281-22,800, NT $22,801-28,000, NT$28,001-36,300, NT$36,301-45,800, and > NT$45,801. The degree of urbanization of the residence areas was divided into 7 ranks: 1st rank represents the highest degree of urbanization, and 7th rank refers to the lowest degree of urban development.[21] Catastrophic illnesses/injuries consist of 30 kinds of disease or injury such as cancers, leukemia, stroke, end-stage renal disease, acquired immune deficiency syndrome (AIDS), rare diseases, coma, and so on., which were defined by the National Health Insurance Administration.
Comorbidity is measured by Deyo’s Charlson Comorbidity Index (CCI), which is the CCI modified by Deyo, in which the CCI score and postoperative complications, mortality rates, and duration and cost of hospitalization are significantly correlated.[22] Therefore, Deyo’s CCI is the method most commonly adopted in topics related to comorbidity.[23] CCI scores were divided into the 2 levels of 0 and ≥1. The diabetes complications severity index (DCSI) was adopted based on the 7 diabetes complications classified by Young et al: retinopathy, nephropathy, neuropathy, cerebral vascular disease, cardiovascular disease, peripheral vascular disease, and metabolic disease.[24] DCSI scores are divided into the 2 levels of 0 and ≥1.

The main medical institute is defined as the institute that the given research subject visited the greatest number of times. The patients’ main medical institutes were also classified into four levels: medical centers; regional hospitals; district hospitals; and other medical clinics. Hospitals were then divided into public and non-public hospitals. Based on the annual service volume of the research subject’s attending physician, a quartile method was applied to divide the service volumes into low (< 25%), mid (25—75%), and high (> 75%) levels for subsequent analysis.

Much of the literature has shown correlations between the use of glucocorticoids, anticonvulsants, loop diuretics, calcium, vitamin D, and bisphosphonates with hip fractures.[15–11] Therefore, medication use is defined as having used of the aforementioned medications Non-long-term use refers to less than 3 months of use of the aforementioned medications, whereas long-term use is defined as using the aforementioned drugs for 3 months or more.

2.4. Statistical analysis

When we conducted the PS matching method, the dependent variable was whether or not the T2DM patients enrolled in a P4P program. The independent variables which were used in the logistic regression model to predict the likelihood of P4P enrollment for T2DM patients included age, gender, monthly salary, comorbid condition, and severity of diabetes complications. The PSM was performed by using the greedy matching by digit without replacement to form a subject matching set with a 1:1 matching ratio. The algorithm performed the “best” match first, followed by the “next best” match in hierarchical sequence, until no more matches could be made. Best matches were those with the highest digit match on propensity score. Approximately 25% of total study population were matched in the final matched sample. We performed the PS matching method using the SAS software, version 9.4. The matching macro presented here was OneToManyMTC.

In this study, we utilized descriptive statistics to distinguish characteristic differences between enrollees and non-enrollees and to study the distribution of the control variables. In addition to calculating the frequency and percentages, chi-squared test was used to determine any significant statistical differences (P < .05) for each variables. We used the log-rank test for inferential statistical analysis to test for any statistically significant difference (P < 0.05) between enrollment in P4P and each control variables and incidence of hip fractures in T2DM patients.

The Cox proportional hazards model was applied to investigate the influence of enrolling in P4P and P4P compliance as well as other factors on the risk of hip fractures after controlling for related variables (including patient characteristics, health status, characteristics of healthcare organization and medication status). Additionally, stratified analysis of DCSI was conducted to investigate whether enrolling in P4P had an influence on the incidence of hip fractures for T2DM patients with various severities of diabetes complications.

We tested the assumption of proportional hazards model. The method was plotting log (-log (survival probability)) versus log (survival time) curves. If the 2 lines are not parallel or intersect, the assumption of proportional hazards is invalid. If the assumption of proportional hazards is invalid, we would add a time variable to the model and used the extended Cox proportional hazard model for further analyses.

Finally, we used the bootstrap method to perform sensitivity analysis by random sampling with replacement. We randomly selected 10,000 patients from both P4P enrollee group and the matched P4P non-enrollee group, respectively, and repeatedly sampled 1000 times. Sensitivity analysis aimed to explore the robustness of the main findings.

In this study, all statistical analyses were performed using the SAS software, version 9.4 (SAS Institute Inc., Cary, NC). All reported P values were 2-sided, and P values less than .05 were considered statistically significant.

3. Results

3.1. Enrollment and patient characteristics

Between 2001 and 2012, 1,618,740 patients were diagnosed with type 2 diabetes (T2DM). A total of 528,060 patients were excluded, of which 210,210 were diagnosed with T2DM for more than 1 year before participating in the P4P program; 56,312 died within 3 months after diagnosed with T2DM; 17,214 patients had hip fractures before they were diagnosed with T2DM; 1019 patients had hip fractures within 3 months after they had been diagnosed with T2DM; 17,483 patients had missing data and 225,822 patients were under 45 years of age. A total of 1,090,680 patients were included in the analysis, of which 127,476 were P4P enrollees and 963,204 were P4P non-enrollees (Table 1). Males constituted a majority (comprising 52.04%); most of the patients were aged between 45 and 54 (comprising 31.06% of the total); and the majority of patients had never enrolled in P4P (comprising 88.31%). In the variates of gender, patient age, monthly salary, severity of CCI and DCSI, the characteristics of non-enrollees and enrollees exhibited significant differences (P < .05). Patients who were aged (≥ 75 years old), had low socioeconomic status (low income households), had comorbidity (CCI ≥ 1), and had diabetes complications (DCSI ≥ 1) enrolled less in P4P (Table 1).

Of 1,090,680 T2DM patients, 21,738 (1.99%) had hip fractures. In 963,204 non-P4P enrollees, 20,130 (2.09%) had hip fractures. Hip fractures occurred in 1608 (1.26%) of 127,476 P4P enrollees (Table 1).

The PSM was applied by using a 1:1 matching ratio. After using the greedy matching by digit without replacement method, a total of 252,266 patients were included in the analysis, of which 126,133 were P4P enrollees and 126,133 were P4P non-enrollees. The proportion of matched sample size was approximately 23.1%.

After the matching process, the 2 groups of patients exhibited no significant difference (P > .05) in the variates for gender, age, monthly salary, CCI, and DCSI (Table 1).
Table 1
Summary of study population before and after propensity score matching.

| Category | Before Matching | After Matching | P value |
|----------|-----------------|----------------|---------|
|          | Total Population (1,090,680) | Non-P4P (963,204) | P4P (127,476) |          |
|          | N % | N % | N % | P value | N % | N % | N % | P value |
| Patient Characteristics | | | | | | | | |
| Gender | | | | | | | | |
| Female | 523,057 | 47.96 | 461,062 | 47.87 | 61,995 | 48.63 | .001 | 122,629 | 48.61 | 61,292 | 48.59 | 61,337 | 48.63 | .001 |
| Male | 567,623 | 52.04 | 502,142 | 52.13 | 65,481 | 51.37 | .001 | 129,637 | 51.39 | 64,841 | 51.41 | 64,796 | 51.37 | .001 |
| Age, yr | 62.33±11.04 | 62.72±11.17 | 59.38±9.51 | .961 | 65–74 | 249,725 | 22.90 | 224,753 | 23.33 | 49,972 | 19.59 | .001 | 49,396 | 19.58 | 24,734 | 19.61 | 24,661 | 19.55 | .001 |
| ≥75 | 169,146 | 15.51 | 150,052 | 16.56 | 9,994 | 7.53 | .001 | 19,104 | 7.57 | 9,572 | 7.59 | 9,532 | 7.56 | .001 |
| Monthly salary (NTD) | | | | | | | | |
| Low-income | 5,501 | 0.50 | 5,042 | 0.52 | 459 | 0.36 | .001 | 481 | 0.33 | 382 | 0.30 | 459 | 0.36 | .001 |
| ≥17280 | 162,062 | 14.86 | 142,092 | 14.75 | 19,970 | 15.67 | .001 | 23,817 | 9.25 | 17,217 | 13.65 | 13,671 | 10.84 | .001 |
| 17281–22880 | 418,299 | 38.35 | 371,346 | 38.55 | 46,953 | 36.83 | .001 | 53,045 | 19.94 | 46,734 | 35.73 | 24,304 | 18.97 | .001 |
| 22881–28800 | 157,035 | 14.40 | 140,547 | 14.59 | 16,488 | 12.93 | .001 | 16,488 | 6.25 | 16,299 | 12.92 | 13,671 | 10.84 | .001 |
| 28801–36300 | 99,400 | 9.11 | 87,045 | 9.04 | 12,355 | 9.69 | .001 | 12,202 | 4.49 | 12,132 | 9.62 | 12,262 | 9.67 | .001 |
| 36301–45800 | 128,111 | 11.75 | 110,677 | 11.49 | 17,434 | 13.68 | .001 | 17,258 | 6.43 | 17,238 | 13.68 | 17,288 | 13.68 | .001 |
| ≥45800 | 120,272 | 11.03 | 106,455 | 11.05 | 13,817 | 10.84 | .001 | 13,671 | 5.02 | 13,671 | 10.84 | 13,671 | 10.84 | .001 |
| Health Status | | | | | | | | |
| CCI | | | | | | | | |
| 0 | 632,957 | 58.03 | 545,775 | 56.66 | 87,182 | 68.39 | .001 | 79,644 | 31.57 | 39,799 | 31.55 | 39,845 | 31.59 | .001 |
| ≥1 | 457,723 | 41.97 | 417,429 | 43.34 | 40,294 | 31.61 | .001 | 36,000 | 68.43 | 30,001 | 68.43 | 30,001 | 68.43 | .001 |
| DCSI | | | | | | | | |
| 0 | 803,445 | 73.66 | 701,791 | 72.86 | 101,654 | 79.74 | .001 | 201,444 | 79.85 | 100,807 | 79.92 | 100,637 | 79.79 | .001 |
| ≥1 | 267,255 | 26.34 | 261,413 | 27.14 | 52,822 | 20.26 | .001 | 50,582 | 20.15 | 25,262 | 20.08 | 25,496 | 20.21 | .001 |
| Hip fracture | | | | | | | | |
| No | 1,006,942 | 98.01 | 914,074 | 97.91 | 125,868 | 98.74 | .001 | 124,552 | 98.75 | 124,572 | 98.76 | 124,572 | 98.76 | .001 |
| Yes | 21,738 | 1.99 | 20,130 | 2.09 | 1,608 | 1.26 | .001 | 3,142 | 1.25 | 1,581 | 1.25 | 1,561 | 1.24 | .001 |

3.2. Risk Analysis for incidence of hip fracture in T2DM patients

Gender, patient age, monthly salary, degree of urbanization of residence areas, catastrophic illness, CCI, DCSI, medication use (steroids, anticonvulsants, diuretics, calcium, and bisphosphonates), and level of main medical institute were statistically significant (P < .05) by bivariate analysis. No significant statistical differences were found between P4P enrollment and hip fractures (P = .160). However, there was a statistically significant difference in the incidence of hip fractures between P4P non-enrollees, P4P enrollees receiving irregular treatments, and P4P enrollees who received regular treatments (Table 2).

After controlling for other variables, analysis using the Cox proportional hazards model showed that P4P enrollees exhibited lower risks of hip fractures than non-enrollees. The risk of hip fractures for P4P enrollees was 0.92 times that of P4P non-enrollees, with statistically significant differences (hazards ratio [HR] = 0.92; 95% confidence interval [CI]: 0.85–0.99). However, there were no statistically significant differences in the effect of hip fractures between P4P non-enrollees and P4P enrollees who received irregular treatment (HR = 0.94, 95% CI: 0.87–1.03). Using the extended Cox proportional hazard model, P4P enrollees who received regular treatment had lower risk of hip fracture than that of P4P non-enrollees in the first 4 years (HR = 0.90; 95% CI: 0.84–0.96), but there was no statistical difference between these 2 groups after 4-year enrollment (HR = 0.99; 95% CI: 0.93–1.06) (Table 3).

In the Cox proportional hazards model, female patients, higher age groups, low income households, presence of catastrophic illness, and patients with diabetes complications (DCSI ≥1) exhibited relatively higher risks of hip fracture (P < .05). Female patients exhibited a risk of hip fracture 1.50 times that of male patients (HR = 1.50; 95% CI: 1.39–1.62). In terms of age, every 10-year increment beyond the reference group of 45 to 54-year-old patients showed increased risks of hip fractures. When patient age exceeds 75, the risk of hip fracture is 21.29 times that of the 45 to 54-year-old patient group (HR = 21.29; 95% CI: 18.60–24.37). Patients with catastrophic illness exhibited risks of hip fractures 1.27 times that of those without catastrophic illness (HR = 1.27; 95% CI: 1.10–1.46). As for DCSI, the risk of hip fractures for patients with diabetes complications (DCSI ≥1) was 1.22 times that of those without diabetes complications (HR = 1.22; 95% CI: 1.13–1.32). The risk of hip fractures for patients on long-term diuretic use was 0.90 times that of those on non-long-term diuretic use (HR = 0.90; 95% CI: 0.82–0.98) (Table 3).

3.3. Influence of P4P Enrollment on the risks of hip fractures for diabetic patients with varying DCSIs

To further investigate the influence of enrollment on the risk of hip fractures for T2DM patients with varying DCSIs, the subjects...
## Table 2
Bivariate analyses: relationships between hip fracture and relevant variables in type 2 diabetic patients.

| Variable                        | Total Population (N = 252,266) | No Hip Fracture (N = 248,124) | Hip Fracture (N = 3,142) | P-value (Log-rank) |
|---------------------------------|---------------------------------|-------------------------------|--------------------------|--------------------|
| **P4P participation**           |                                 |                               |                          |                    |
| No                              | 126,133                         | 124,552                       | 1,581                    | 1.25               |
| Yes                             | 126,133                         | 124,572                       | 1,561                    | 1.24               |
| **Compliance**                  |                                 |                               |                          | <.001              |
| Non-P4P                         | 126,133                         | 124,552                       | 1,581                    | 1.25               |
| P4P but irregular treatment     | 59,395                          | 58,492                        | 903                      | 1.52               |
| P4P and gular treatment         | 66,738                          | 66,080                        | 658                      | 0.99               |
| **Patient Characteristics**     |                                 |                               |                          |                    |
| **Gender**                      |                                 |                               |                          | <.001              |
| Male                            | 122,629                         | 120,688                       | 1,941                    | 1.58               |
| Female                          | 129,637                         | 128,436                       | 1,201                    | 0.93               |
| **Age (years)**                 |                                 |                               |                          | <.001              |
| 45–54                           | 97,548                          | 97,250                        | 298                      | 0.31               |
| 55–64                           | 86,219                          | 85,564                        | 655                      | 0.76               |
| 65–74                           | 49,395                          | 48,206                        | 1,189                    | 2.41               |
| ≥75                             | 19,104                          | 18,104                        | 1,000                    | 5.23               |
| **Monthly salary (NTD)**        |                                 |                               |                          | <.001              |
| Low-income                      | 972                             | 953                            | 19                       | 1.95               |
| >17280                          | 5,258                           | 5,223                          | 35                       | 0.67               |
| >17281–22080                    | 47,955                          | 47,440                         | 515                      | 1.07               |
| >22081–28800                    | 41,144                          | 40,761                         | 363                      | 0.93               |
| >28801–36300                    | 14,970                          | 14,887                         | 83                       | 0.55               |
| ≥36301                          | 18,148                          | 18,068                         | 80                       | 0.44               |
| **Level of urbanization**       |                                 |                               |                          | <.001              |
| 1                               | 39,331                          | 39,082                        | 249                      | 0.63               |
| 2                               | 45,410                          | 45,047                        | 363                      | 0.8                |
| 3                               | 20,755                          | 20,572                        | 183                      | 0.68               |
| 4                               | 23,890                          | 23,612                        | 278                      | 1.16               |
| 5                               | 3,014                           | 2,985                          | 29                       | 0.96               |
| 6                               | 6,114                           | 6,046                          | 68                       | 1.11               |
| 7                               | 5,514                           | 5,461                          | 53                       | 0.96               |
| **Health status**               |                                 |                               |                          |                    |
| Catastrophic illnesses          |                                 |                               |                          | <.001              |
| No                              | 237,415                         | 234,502                       | 2,913                    | 1.23               |
| Yes                             | 14,851                          | 14,622                        | 229                      | 1.54               |
| **CCI**                         |                                 |                               |                          | <.001              |
| 0                               | 172,622                         | 170,859                       | 1,763                    | 1.02               |
| ≥1                              | 78,644                          | 78,265                        | 1,379                    | 1.73               |
| **DCSI**                        |                                 |                               |                          | <.001              |
| 0                               | 201,444                         | 199,257                       | 2,187                    | 1.09               |
| ≥1                              | 50,822                          | 49,907                        | 952                      | 1.88               |
| **Medication Use**              |                                 |                               |                          |                    |
| Steroids                        |                                 |                               |                          | <.001              |
| Non-chronic use                 | 247,500                         | 244,441                       | 3,059                    | 1.24               |
| Chronic use                     | 4,766                           | 4,683                         | 83                       | 1.74               |
| **Anti-epileptics**             |                                 |                               |                          | <.001              |
| Non-chronic use                 | 235,404                         | 232,564                       | 2,840                    | 1.21               |
| Chronic use                     | 16,862                          | 16,560                        | 302                      | 1.79               |
| **Diuretics**                   |                                 |                               |                          | <.001              |
| Non-chronic use                 | 211,842                         | 209,443                       | 2,499                    | 1.18               |
| Chronic use                     | 40,324                          | 39,681                        | 643                      | 1.59               |
| **Calcium**                     |                                 |                               |                          | <.001              |
| Non-chronic use                 | 237,653                         | 234,859                       | 2,794                    | 1.18               |
| Chronic use                     | 14,813                          | 14,265                        | 348                      | 2.38               |
| **Vitamin D**                   |                                 |                               |                          | 164                |
| Non-chronic use                 | 251,236                         | 248,115                       | 3,121                    | 1.24               |
| Chronic use                     | 1,030                           | 1,099                         | 21                       | 2.04               |
| **Bisphosphonate**              |                                 |                               |                          | <.001              |
| Non-chronic use                 | 249,043                         | 246,022                       | 3,021                    | 1.21               |
| Chronic use                     | 3,223                           | 3,102                         | 121                      | 3.75               |
| **Primary physician service volume** |                             |                               |                          | 137                |
| Low                             | 2,329                           | 2,306                          | 23                       | 0.99               |
| Moderate                        | 38,814                          | 38,108                        | 506                      | 1.31               |
| High                            | 211,323                         | 208,710                       | 2,813                    | 1.24               |
| **Level of health care organization** |                               |                               |                          | <.001              |
| Medical center                  | 47,457                          | 46,898                        | 559                      | 1.18               |
| Regional                        | 74,624                          | 73,609                        | 1,051                    | 1.36               |
| District                        | 43,624                          | 42,937                        | 687                      | 1.57               |
| Other clinic                    | 86,561                          | 85,680                        | 881                      | 1.02               |
| Ownership of organization       |                                 |                               |                          | .007               |
| Public                          | 59,207                          | 58,391                        | 816                      | 1.38               |
| Nonpublic                       | 193,059                         | 190,733                       | 2,326                    | 1.20               |

Co = Charlson’s comorbidity index, DCSI = diabetes complications severity index, NTD = new Taiwan dollar, P4P = pay for performance enrollees.
## Factors associated with hip fracture risk in type 2 diabetic patients, including P4P participation status and other variables.

|                                | Adjusted Cox model (Non P4P vs P4P) | Adjusted Cox model (Non P4P vs Irregular P4P) | Adjusted Cox model (Non P4P vs Regular P4P) |
|--------------------------------|------------------------------------|---------------------------------------------|------------------------------------------|
|                                | HR                                 | 95%CI                                       | P-Value                                  | HR                                 | 95%CI                                       | P-Value                                  | HR                                 | 95%CI                                       | P-Value                                  |
| P4P participation              |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| No (ref.)                       | 0.92                               | 0.85                                        | 0.99                                     | 0.019                               | 0.94                                        | 0.87                                      | 1.03                                 | 0.180                                        |                                          |
| Compliance                      |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Non-P4P (ref.)                  |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| P4P but irregular treatment    |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Compliance                      |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Non-P4P (ref.)                  |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| P4P with regular treatment     |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| ≤4 year                         |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| >4 year                         |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Patient Characteristics         |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Gender                          |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Male (ref.)                     |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Age, ≥40-54 (ref.)              |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| <55-64                          | 2.59                               | 2.26                                        | 2.97                                     | <.001                               | 2.58                                        | 2.19                                      | 2.99                                 | <.001                                        | 2.67                                         | 2.28                                       | 3.14                                     | <.001                               |
| 65-74                           | 2.75                               | 2.66                                        | 8.62                                     | <.001                               | 7.55                                        | 6.52                                      | 8.73                                 | <.001                                        | 7.97                                         | 6.84                                       | 9.28                                     | <.001                               |
| ≥75                             | 21.25                             | 18.60                                       | 24.37                                    | <.001                               | 20.43                                       | 17.53                                      | 23.81                                 | <.001                                        | 22.87                                       | 19.49                                      | 26.85                                    | <.001                               |
| Monthly salary (NTD)            |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Low-income (ref.)               |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| <17280                          | 0.57                               | 0.36                                        | 0.80                                     | <.015                               | 0.72                                        | 0.41                                      | 1.29                                 | 0.272                                        | 0.54                                         | 0.32                                       | 0.91                                     | <.020                               |
| 127281-22080                    | 0.66                               | 0.43                                        | 1.03                                     | <.007                               | 0.88                                        | 0.50                                      | 1.56                                 | 0.669                                        | 0.58                                         | 0.35                                       | 0.96                                     | <.035                               |
| 22081-28800                     | 0.59                               | 0.38                                        | 0.93                                     | <.021                               | 0.77                                        | 0.43                                      | 1.36                                 | 0.363                                        | 0.53                                         | 0.31                                       | 0.89                                     | <.016                               |
| 28801-36300                     | 0.52                               | 0.33                                        | 0.82                                     | <.005                               | 0.71                                        | 0.40                                      | 1.28                                 | 0.258                                        | 0.39                                         | 0.23                                       | 0.67                                     | <.001                               |
| ≥36301-45800                    | 0.42                               | 0.26                                        | 0.66                                     | <.001                               | 0.56                                        | 0.31                                      | 1.00                                 | 0.505                                        | 0.37                                         | 0.21                                       | 0.62                                     | <.001                               |
| Health status                   |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Catastrophic illnesses (ref.)   |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Yes                             | 1.12                               | 0.92                                        | 1.38                                     | <.007                               | 1.15                                        | 0.91                                      | 1.45                                 | 0.232                                        | 1.12                                         | 0.88                                       | 1.42                                     | <.377                               |
| Chronic use                     |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Non-chronic use (ref.)          |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Steroids                        |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Chronic use                     |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Anti-epileptics                 |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Non-chronic use (ref.)          |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Diuretics                       |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Non-chronic use (ref.)          |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Calcium                         |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Non-chronic use (ref.)          |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Vitamin D                       |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Non-chronic use (ref.)          |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Bisphosphonate                  |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Non-chronic use (ref.)          |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Primary physician service volume|                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Low-income (ref.)               |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Moderate                        | 1.12                               | 0.74                                        | 1.74                                     | 0.001                               | 1.04                                        | 0.69                                      | 1.52                                 | 0.850                                        | 1.00                                         | 0.68                                       | 1.71                                     | .753                                |
| High                            | 1.00                               | 0.66                                        | 1.50                                     | <.000                               | 0.92                                        | 0.61                                      | 1.39                                 | 0.684                                        | 0.97                                         | 0.61                                       | 1.52                                     | .879                                |
| Level of health care organization|                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| Medical center (ref.)           |                                    |                                             |                                          |                                    |                                             |                                          |                                    |                                             |                                          |
| COPC                            | 1.01                               | 0.93                                        | 1.10                                     | 0.753                               | 1.00                                        | 0.91                                      | 1.10                                 | 0.980                                        | 1.06                                         | 0.96                                       | 1.17                                     | .256                                |

COI = Charlson’s comorbidity index, CI = confidence interval, DCSI = diabetes complications severity index, HR = hazards ratio, NTD = new Taiwan dollar, P4P = pay for performance.

Lee et al. Medicine (2020) 99:12

Medicine
in this study were divided into 2 groups: those without complications of DM (DCSI = 0), and those with complications of DM (DCSI ≥ 1). Stratified analysis showed that patients without DM complications (DCSI = 0) who enrolled in P4P had lower risks of hip fractures than P4P non-enrollees (HR = 0.90; 95% CI: 0.82–0.98). P4P enrollees with a DCSI of 0 who received regular treatment showed a lower risk of hip fracture in the first 4 years (HR = 0.90; 95% CI: 0.83–0.97), but there was no statistical difference after enrollment more than 4 years (HR = 0.98; 95% CI: 0.91–1.06) compared to those P4P non-enrollees (Table 4).

### 4. Discussion

Our study showed that P4P enrollees had lower risk of hip fractures than non-enrollees (HR = 0.92; 95% CI: 0.85–0.99). Although patients enrolled in P4P who received irregular treatment exhibited relatively low risks of hip fractures, but no significant statistical difference was found (HR = 0.94; P = .180). Frequency of outpatient visits and laboratory measurement items increased in P4P enrollees.\[18\] Regardless of short-term (<1 year) or long-term (>3 years), P4P enrolment improved glycemic control.\[26,29\] Moreover, patients who received regular treatment may receive increased medical consulting and health education, more thorough testing and exams, and regular drug therapy. Therefore, those with regular treatment can achieve stricter glycemic control.\[20\] Oie et al found that inadequate glycemic control increased the risk of hip fractures.\[27\] The aforementioned literature may explain why the P4P enrollees with irregular treatment do not significantly reduce the risk of hip fracture.

The hip fracture patients are defined as patients with hip fractures who require hospitalization and surgical treatment. The orthopaedic surgeons always did the procedure as an urgent operation. The date of surgery can be retrieved from NHIRD. It means that the NHIRD contained information about when the hip fracture occurred. We hypothesized that the Cox proportional hazards model was time independent. We tested the assumption of proportional hazards model. The results showed that the effect of hip fracture between P4P non-enrollees and enrollees were independent of time (P = .053). The effects of hip fracture between P4P non-enrollees and enrollees receiving irregular treatment were also time independent (P = .706). However, the effects of hip fracture occurrence between P4P non-enrollees and enrollees who received regular treatment were time dependent (P = .003). Therefore, the participation time was divided into ≤4 years and >4 years to assess the risk of hip fracture between P4P non-enrollees and enrollees receiving regular treatment.

P4P enrollees who received regular treatment had lower risk of hip fracture than that of P4P non-enrollees in the first 4 years (HR = 0.90; 95% CI: 0.84–0.96), but there was no statistical difference between these 2 groups after 4-year enrollment (HR = 0.99; 95% CI: 0.93–1.06). A possible explanation is that after enrollment more than 4 years, the aging effect that may worsen bone quality through progressive osteoporosis is more pronounced than P4P protection.

We further used the bootstrap method to perform sensitivity analysis to explore the robustness of the main findings. The results also showed P4P enrollees had a lower risk of hip fracture than non-enrollees (mean HR = 0.93; 95% CI: 0.91–0.96).

In regard to medication status, long-term loop diuretic administration reduced the risks of hip fractures. Schoofs et al (2003) also published similar findings, indicating that the long-term use of thiazide loop diuretics reduced the risks of hip fractures.\[19\] The literature has shown that glucocorticoids and anticonvulsants increase the risks of fractures.\[5–7\] however, calcium, vitamin D, and bisphosphonates reduce the risks of fractures.\[10\] Use of glucocorticoids, anticonvulsants, calcium, vitamin D, and bisphosphonates exerted no significant influence on the risk of hip fracture in this study.

This study showed that the risks of hip fractures in low income households were higher than those with higher levels of monthly salary. Moreover, relatively few patients with low socioeconomic status enrolled in P4P (P < .05). This may be related to inequality of care and increased incidence of diabetes associated with poverty.\[26\] physicians’ intentional or unintentional lack of attention in medical care,\[29\] and difficulties for patients with low socioeconomic status in establishing adequate relationships and communication with physicians.\[30\] It also showed that comparatively fewer elderly (≥75) patients and patients with suboptimal health conditions (presence of catastrophic illness or complications of diabetes) enrolled in P4P (P < .05). It can be due to selective bias in which the physician tends to select and treat younger and healthier patients in order to aid the physician in acquiring better P4P program outcomes and grants.\[1,12\]

The literature has previously investigated the relationships between DCSI and mortality, hospitalization, and healthcare utilization. They have shown that higher DCSI scores also result in higher mortality, hospitalization, and healthcare utilization. However, there was no literature to investigate the relationship between DCSI and the incidence of hip fractures. Our study showed that the risk of hip fractures for patients with diabetes complications (DCSI ≥ 1) was 1.22 times that of those without diabetes complications (DCSI = 0). Stratified analysis showed that patients without diabetes complications who enrolled in P4P reduced the risk of hip fractures by 10% over that of non-P4P

| DCSI | Non-P4P vs P4P | Non-P4P vs P4P regular treatment <4 yr | Non-P4P vs P4P regular treatment ≥4 yr |
|------|---------------|--------------------------------------|--------------------------------------|
| 0    | HR (95% CI)   | P-value                              | HR (95% CI)                           |
|      |               |                                      |                                       |
|      | 0.90 (0.82–0.98) | .013                                |                                       |
| ≥1   | 0.96 (0.84–1.10) | .551                                |                                       |

CI = confidence interval, DCSI = diabetes complication severity index, P4P = pay for performance, All Cox proportional hazard models have been controlled for other relevant variables.

Table 4

Stratified analyses: influence of P4P participation status on the risk of hip fracture for type 2 diabetic patients with varying DCSI.
participants. There was no statistically significant difference in the risk of hip fracture between the non-P4P and P4P groups when the patient was diagnosed with diabetic complications (DCS ≤ 1). A possible explanation is that patients without complications from T2DM had comparatively better glycemic control. Moreover, after enrolling in P4P and receiving regular medical intervention, such patients were able to further improve their glycemic control. Good glycemic control can reduce the risk of hip fractures. This logically explains how enrollment in P4P and regular treatment has optimal outcomes in hip fracture risk reduction for T2DM patients who have had no complications from DM.

We found that the enrollees accounted for a mere 11.7% of all diabetic patients, in which only 52.9% of P4P enrollees received regular medical attention. It shows that P4P enrollment still has room for improvement. Even after P4P enrollment, more effort is needed in answering the question of how to improve compliance with DM treatment guidelines, in order to establish a regular treatment model. Other concerns remain within P4P. Although National Health Insurance provides universal medical treatment, patients with higher ages, multiple complications, and high severities of diabetes are excluded from P4P. Reasons include communication difficulties with medical and nursing staff due to visual and hearing impairments; low socioeconomic status; low education levels; and mobility problems in seeking medical attention.[31, 32] This study also showed similar findings in which patients of higher age groups (≥ 75), low income households, and suboptimal health conditions are enrolled in P4P at lower rates. However, these patients also exhibit relatively higher risks of hip fractures. These deficiencies significantly compromise P4P performance. Therefore, these patients should be the focus of our future efforts.

5. Limitations

The data in this study was retrieved from a secondary database. Therefore, the influence of patients’ lifestyles (including diet), health behaviors (including smoking, alcohol abuse, and regular exercise), biochemical parameters (sugar, HbA1C), body mass index (presence or absence of obesity), and bone density (presence or absence of osteoporosis) were unable to be determined and thus could not be included in this study. The literature showed that considering the matching nature of the sample, the standard error can be estimated more accurately than when the matching nature is not considered.[33] We did not account for the matched nature of the propensity-score matched sample when estimating the significance of the treatment effect. This is another limitation of our study.

6. Conclusion

This study indicated that patients with higher ages, low income households, and DCSIs ≥ 1 exhibited significantly higher risks of hip fracture. T2DM patients enrolled in P4P can reduce the risks of hip fracture incidence. Stratified analysis showed that patients without DM complications who participated in P4P demonstrated significantly lower risks of hip fracture. Therefore, we recommend removing obstacles for disadvantaged patients (those in poverty, the aged, and those with severe diabetes conditions) to enroll in P4P programs. In addition, early participation in the P4P program in patients without DM complications can effectively reduce the risk of hip fracture. Finally, we recommend that future researchers can include relevant test data such as glycated hemoglobin (HbA1c) and bone density (DXA) to verify the effectiveness of P4P in reducing the incidence of hip fracture.

Acknowledgments

We are grateful for using the National Health Insurance Research Database provided by the Science Center of the Ministry of Health and Welfare, Taiwan. We are also grateful to Health Data Science Center, China Medical University Hospital for providing administrative, technical and funding support.

Author contributions

Conceived and designed the experiments: YHL PTK WCT. Performed the experiments: YHL PTK WYG SLK WCT. Analyzed the data: PTK WYG WCT. Contributed reagents/materials/analysis tools: YHL PTK WYG SLK WCT. Wrote the paper: YHL PTK SLK WCT.

Conceptualization: Yung-Heng Lee, Pei-Tseng Kung, Wen-Chen Tsai.

Data curation: Yung-Heng Lee, Pei-Tseng Kung, Wei-Yin Kuo, Su-Ling Kao, Wen-Chen Tsai.

Formal analysis: Pei-Tseng Kung, Wei-Yin Kuo, Wen-Chen Tsai.

Funding acquisition: Pei-Tseng Kung, Wen-Chen Tsai.

Investigation: Pei-Tseng Kung, Su-Ling Kao, Wen-Chen Tsai.

Methodology: Yung-Heng Lee, Pei-Tseng Kung, Wei-Yin Kuo, Su-Ling Kao, Wen-Chen Tsai.

Project administration: Yung-Heng Lee, Pei-Tseng Kung, Wei-Yin Kuo, Su-Ling Kao, Wen-Chen Tsai.

Resources: Yung-Heng Lee, Pei-Tseng Kung, Wei-Yin Kuo, Su-Ling Kao, Wen-Chen Tsai.

Software: Yung-Heng Lee, Pei-Tseng Kung, Wei-Yin Kuo, Su-Ling Kao, Wen-Chen Tsai.

Supervision: Yung-Heng Lee, Pei-Tseng Kung, Wen-Chen Tsai.

Validation: Yung-Heng Lee, Pei-Tseng Kung, Wen-Chen Tsai.

Visualization: Yung-Heng Lee, Pei-Tseng Kung, Wen-Chen Tsai.

Writing – original draft: Yung-Heng Lee, Wen-Chen Tsai.

Writing – review and editing: Yung-Heng Lee, Wen-Chen Tsai.

Wen-Chen Tsai orcid: 0000-0002-9684-0789.

References

[1] Ministry of Health and Welfare and Statistics Department. Statistical analysis of the results of the 2016 death; Available at: http://www.mohw.gov.tw/CHT/DOS/Statistic.aspx?list_no=312&food_list_no=6201. Accessed Nov. 7, 2018.

[2] Jiang YD, Chang CH, Tai TY, et al. Incidence and prevalence rates of diabetes mellitus in Taiwan: analysis of the 2000-2009 Nationwide Health Insurance database. J Formos Med Assoc 2012;111:599–604.

[3] Kanis JA, Odén A, McCloskey EV, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 2012;23:2239–56.

[4] Abrahamsen B, van Staa T, Arieley R, et al. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 2009; 20:163–50.

[5] Vestergaard P, Olsen ML, Paaske Johnsen S, et al. Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark. J Intern Med 2003;254:486–93.

[6] Pennisi P, Trombetti A, Rizzoli R. Glucocorticoid-induced osteoporosis and its treatment. Clin Orthop Relat Res 2006;443:39–47.

[7] Ensrud KE, Waclawik TS, Blackwell T, et al. Ameptileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004;62:2051–7.

[8] Bischoff-Ferrari HA, Rees JR, Grau MV, et al. Effect of calcium supplementation on fracture risk: a double-blind randomized controlled trial. Am J Clin Nutr 2008;87:1945–51.
Cauley JA, Lacroix AZ, Wu L, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 2008;149:242–50.

Holder KK, Kerley SS. Alendronate for fracture prevention in postmenopause. Am Fam Physician 2008;78:579–81.

Schoofs MW, van der Klift M, Hofman A, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003;139:476–82.

Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495–505.

Koh WP, Wang R, Ang LW, et al. Diabetes and risk of hip fracture in the Singapore Chinese Health Study. Diabetes Care 2010;33:1766–70.

Chen HF, Ho CA, Li CY. Increased risks of hip fracture in diabetic patients of Taiwan: a population-based study. Diabetes Care 2008;31:75–80.

Lee TT, Cheng SH, Chen CC, et al. A pay-for-performance program for diabetes care in Taiwan: a preliminary assessment. Am J Manag Care 2010;16:65–9.

Chen JY, Tian H, Taira Juarez D, et al. The effect of a PPO pay-for-performance program on patients with diabetes. Am J Manag Care 2010;16:11–9.

Yen SM, Kung PT, Sheen YJ, et al. Factors related to continuing care and interruption of P4P program participation in patients with diabetes. Am J Manag Care 2016;22:e18–30.

Cheng SH, Lee TT, Chen CC. A longitudinal examination of a pay-for-performance program for diabetes care: evidence from a natural experiment. Med Care 2012;50:109–16.

Yao Xi, Wang X, Speicher PJ, et al. Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies. J Natl Cancer Inst 2017;109:1–9.

Yu HC, Tsai WC, Kung PT. Does the pay-for-performance programme reduce the emergency department visits for hypoglycaemia in type 2 diabetic patients? Health Policy Plan 2014;29:732–41.

Liu CY, Chaang HY, Chen YL, KY, et al. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag 2006;4:1–22.